While these results demonstrate the therapeutic potential of targeting MTs in cardiomyocytes in patients with LMNA cardiomyopathy, we have not directly tested the ability of MT disruption to rescue cardiac function in already developed cardiomyopathy. The gene discussed is TIMM8A; the disease is cardiomyopathy.